Related Experiment Video
Updated: Aug 16, 2026
05:46
Introduction of Intracapsular Rotary-cut Procedures (IRCP): A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation
Published on: January 17, 2019
Mifepristone (RU 486) treatment of meningiomas
S W Lamberts1, H L Tanghe, C J Avezaat
1Erasmus University, Rotterdam, The Netherlands.
Journal of Neurology, Neurosurgery, and Psychiatry
|June 1, 1992
Summary
Mifepristone (RU 486) was tested on 10 patients with inoperable brain tumors called meningiomas. The drug controlled tumor growth in six patients, with three showing shrinkage.
Area of Science:
- Neuro-oncology
- Endocrinology
Background:
- Meningiomas are common, typically benign brain tumors.
- Recurrent or inoperable meningiomas pose significant clinical challenges.
- Progesterone receptors are present in most meningiomas.
Purpose of the Study:
- To evaluate the efficacy of mifepristone, an anti-progestational drug, in treating recurrent or inoperable meningiomas.
- To assess the impact of mifepristone on tumor growth and patient symptoms.
Main Methods:
- Ten patients with 12 inoperable meningiomas received 200 mg of mifepristone daily for 12 months.
- Tumor size was monitored using CT scans.
- Patient-reported symptoms and side effects were recorded.
Main Results:
- Tumor growth control (stable disease) was achieved in 6 out of 10 patients.
- Tumor shrinkage was observed in 3 of the 6 patients with controlled growth.
- Five patients reported decreased headaches and improved well-being.
- Common side effects included nausea, vomiting, and tiredness, which were managed with prednisone.
Conclusions:
- Mifepristone demonstrates potential in controlling the growth of inoperable meningiomas.
- Further research is warranted to explore mifepristone's therapeutic role in neuro-oncology.
